• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

CVM Publications - Detail

  • Print
  • Share
  • E-mail
-
 
TITLE:  Preliminary studies of offspring exposure to phenylbutazone and ivermectin during the perinatal period in a Holstein cow-calf model
 
AUTHORS:  Chamberlain PL;Fowler BA;Sexton MJ;Peggins JO;Bredow J;
 
YEAR:  2003
 
JOURNAL ABBREV:  Toxicol Appl Pharmacol
 
MONTH:  Mar
 
TYPE:  JOUR
 
REFMAN INDEX:  504
 
JOURNAL FULL:  Toxicology and applied pharmacology
 
VOLUME:  187
 
ISSUE:  3
 
START PAGE:  198
 
END PAGE:  208
 
KEYWORDS:  administration & dosage;analysis;Animals;Animals,Newborn;Animals,Suckling;Anthelmintics;Anti-Inflammatory Agents;Anti-Inflammatory Agents,Non-Steroidal;blood;Cattle;chemistry;Female;Food;Half-Life;Ivermectin;Lactation;Maternal-Fetal Exchange;Milk;Models,Animal;pharmacokinetics;Phenylbutazone;Pregnancy;Safety;Solubility;United States;United States Food and Drug Administration;veterinary;Veterinary Medicine;
 
ABSTRACT:  The pregnant Holstein cow and her newborn calf were evaluated as an animal model to study in utero and for lactational drug transfer and offspring exposure. A nonsteroidal antiinflammatory drug, phenylbutazone, and an antiparasitic drug, ivermectin, were tested in the model. Prior to parturition, pregnant cows were dosed orally to steady state with phenylbutazone at 4 g/day or given a single subcutaneous injection of 200 microg ivermectin/kg body wt. The level of drug transferred to calves exposed in utero, in utero combined with lactational exposure, and via lactational exposure only, was measured from days 1 through 7 postpartum. At birth the plasma level in phenylbutazone-exposed calves was approximately one-half the dam's steady-state level. For ivermectin-exposed calves, plasma levels were at or below the limit of quantitation (0.5 ng/ml) at birth, suggesting that placental transfer of ivermectin is limited in the cow. For both drugs, rapid accumulation of the drug in calf plasma occurred with lactational exposure to a mean daily dose of 2 microg ivermectin/kg body wt or 0.1 mg phenylbutazone/kg body wt/day for the first 7 days of life. The accumulation observed in the newborn calf is attributed to the lipid solubility and long elimination half-lives of these drugs. These results demonstrate that drug transfer and offspring exposure can be studied using the cow-calf model. The data also highlight the importance of considering not only the dose but also physicochemical characteristics and pharmacokinetics of the drug in the offspring when evaluating the safety of a newborn's exposure to a drug in breast milk
 
AFFILIATIONS:  Center for Veterinary Medicine, United States Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, USA. pchambe@cvm.fda.gov
 
-
-